Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis

Objective Tolvaptan was first approved for use for cirrhosis in Japan in September 2013. The aim of the study was to examine the effect of tolvaptan, a vasopressin V2 receptor antagonist, on the prognosis of cirrhosis. Methods The effect of tolvaptan was evaluated in 26 patients with cirrhosis treat...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Intern Med
Egile Nagusiak: Iwamoto, Takuya, Maeda, Masaki, Hisanaga, Takuro, Saeki, Issei, Fujisawa, Koichi, Matsumoto, Toshihiko, Hidaka, Isao, Ishikawa, Tsuyoshi, Takami, Taro, Sakaida, Isao
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: The Japanese Society of Internal Medicine 2016
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5109555/
https://ncbi.nlm.nih.gov/pubmed/27746425
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak